{
  "context": {
    "rules": [
      "Rule1: If the research team identifies an impurity in the PlantExtract, then if research on the PlantExtract progressing does not result in the NIH renewing the grant for the PlantExtract, a manufacturing process for the PlantExtract is designed.",
      "Rule2: If funding for the PlantExtract is secured, then if the research team optimizing extraction of the PlantExtract does not lead to the scenario where research on the PlantExtract progressing not resulting in the NIH renewing the grant for the PlantExtract leads to a manufacturing process for the PlantExtract being designed, the PlantExtract project is terminated.",
      "Rule3: If adverse effects of the PlantExtract are reported, then patient recalls for the PlantExtract are issued.",
      "Rule4: If a safety review of the PlantExtract is initiated, then the PlantExtract is toxic.",
      "Rule5: If patient recalls for the PlantExtract are issued, then a safety review of the PlantExtract is initiated.",
      "Rule6: If the FDA launches a regulatory investigation into the PlantExtract, then the PlantExtract is safe for humans.",
      "Rule7: If production of the PlantExtract is halted, then the FDA launches a regulatory investigation into the PlantExtract.",
      "Rule8: If a quality control breach in the PlantExtract is detected, then contamination is found in the PlantExtract.",
      "Rule9: If contamination is found in the PlantExtract, then production of the PlantExtract is halted.",
      "Rule10: If the PlantExtract is toxic, then the FDA does not approve the PlantExtract.",
      "Rule11: Either CompoundX has clinical trials or, if the PlantExtract is synthesized into drug CompoundX, then if the NIH not renewing the grant for the PlantExtract does not lead to the PlantExtract being toxic, the PlantExtract is safe for humans.",
      "Rule12: Either research on the PlantExtract progresses or research on the PlantExtract is stalled.",
      "Rule13: If research on the PlantExtract is stalled, then the NIH renews the grant for the PlantExtract.",
      "Rule14: Either the research team optimizes extraction of the PlantExtract or the research team identifies an impurity in the PlantExtract.",
      "Rule15: If research on the PlantExtract progressing does not lead to the NIH renewing the grant for the PlantExtract, then a manufacturing process for the PlantExtract is not designed.",
      "Rule16: If the research team optimizing extraction of the PlantExtract does not result in the scenario where research on the PlantExtract progressing not leading to the NIH renewing the grant for the PlantExtract leads to a manufacturing process for the PlantExtract being designed, then the PlantExtract project is not terminated.",
      "Rule17: If the NIH not renewing the grant for the PlantExtract does not lead to the PlantExtract being toxic, then a quality control breach in the PlantExtract is detected.",
      "Rule18: If the NIH does not renew the grant for the PlantExtract, then the FDA approves the PlantExtract.",
      "Rule19: If the NIH does not renew the grant for the PlantExtract, then adverse effects of the PlantExtract are reported."
    ],
    "facts": [
      "Fact1: Funding for the PlantExtract is secured.",
      "Fact2: The PlantExtract is synthesized into drug CompoundX.",
      "Fact3: The PlantExtract is not safe for humans.",
      "Fact4: CompoundX does not have clinical trials."
    ]
  },
  "question": "The NIH renews the grant for the PlantExtract."
}